A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL (ACCL1033)

Service: Trial Number:
Principal Investigator: Conducted at:
Orange Coast Memorial
Currently enrolling additional patients:

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a five-year survival rate approaching 80%. Several studies have shown highly significant differences in survival among ethnic and racial groups. The outcome for Hispanics has been intermediate between those for Caucasians and African-Americans. The reason(s) for the observed differences in outcome by ethnicity are not clear. We hypothesize that ethnic/racial difference in systemic exposure to 6-MP during maintenance therapy, due primarily to non-adherence to 6-Mercaptopurine (6-MP), could explain the observed differences in outcome of childhood ALL by race/ethnicity. This investigation, as opposed to the standard procedure which are the ways caregivers normally help patients take their medications as directed, will test the feasibility, utility, and efficacy of a technologically sophisticated, web-based medication scheduling and text-messaging reminder system (REM) that prompts directly observed therapy (DOT) of each dose by a parent or designated caregiver, coupled with a multimedia-based interactive patient education program (MIPE), to increase adherence to daily oral 6MP in children with ALL at high risk for non-adherence.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
The email to associate with this registration.